BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2019;30:2449-63. [PMID: 31575699 DOI: 10.1681/ASN.2019040331] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Nga HS, Palma LMP, Ernandes Neto M, Modelli de Andrade LG. Eculizumab in low-middle income countries: how much does a life cost? J Nephrol 2022. [PMID: 35366215 DOI: 10.1007/s40620-022-01282-4] [Reference Citation Analysis]
2 Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther 2022. [PMID: 35304755 DOI: 10.1111/jcpt.13642] [Reference Citation Analysis]
3 Duineveld C, Bouwmeester R, van der Heijden JW, Berger SP, van de Kar NCAJ, Wetzels JFM; Dutch aHUS Working Group. Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. Clin Kidney J 2021;14:1939-45. [PMID: 34631043 DOI: 10.1093/ckj/sfaa241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Prével R, Delmas Y, Guillotin V, Gruson D, Rivière E. Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes. J Clin Med 2022;11:790. [PMID: 35160242 DOI: 10.3390/jcm11030790] [Reference Citation Analysis]
5 Wu Y, Zuber J, Fu J. Editorial: Immunogenomics of Solid Organ and Hematopoietic Stem Cell Transplantation. Front Immunol 2022;13:878314. [PMID: 35371062 DOI: 10.3389/fimmu.2022.878314] [Reference Citation Analysis]
6 Deghmane AE, Taha S, Taha MK. Global epidemiology and changing clinical presentations of invasive meningococcal disease: a narrative review. Infect Dis (Lond) 2022;54:1-7. [PMID: 34459329 DOI: 10.1080/23744235.2021.1971289] [Reference Citation Analysis]
7 Greenbaum LA, Licht C, Nikolaou V, Al-Dakkak I, Green J, Haas CS, Román-Ortiz E, Cheong HI, Sartz L, Swinford R, Tomazos I, Miller B, Cataland S. Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry. Kidney Int Rep 2020;5:1161-71. [PMID: 32775815 DOI: 10.1016/j.ekir.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Uffing A, Hullekes F, Riella LV, Hogan JJ. Recurrent Glomerular Disease after Kidney Transplantation: Diagnostic and Management Dilemmas. Clin J Am Soc Nephrol 2021;16:1730-42. [PMID: 34686531 DOI: 10.2215/CJN.00280121] [Reference Citation Analysis]
9 Yu H, Wang C, Ke S, Bai M, Xu Y, Lu S, Feng Z, Qian B, Xu Y, Zhou M, Li Z, Yin B, Li X, Hua Y, Zhou Y, Pan S, Fu Y, Ma Y. Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma. Front Immunol 2022;13:892750. [DOI: 10.3389/fimmu.2022.892750] [Reference Citation Analysis]
10 Legendre C, Rebecca-Sberro-Soussan, Zuber J. Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. Kidney Int Rep 2021;6:1489-91. [PMID: 34169186 DOI: 10.1016/j.ekir.2021.04.036] [Reference Citation Analysis]
11 Plasse RA, Olson SW, Yuan CM, Agodoa LY, Abbott KC, Nee R. Prophylactic or Early Use of Eculizumab and Graft Survival in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome in the United States: Research Letter. Can J Kidney Health Dis 2021;8:20543581211003763. [PMID: 33868691 DOI: 10.1177/20543581211003763] [Reference Citation Analysis]
12 Wu Q, Tian X, Gong N, Zheng J, Liang D, Li X, Lu X, Xue W, Tian P, Wen J. Early graft loss due to acute thrombotic microangiopathy accompanied by complement gene variants in living-related kidney transplantation: case series report. BMC Nephrol 2022;23:249. [PMID: 35836191 DOI: 10.1186/s12882-022-02868-7] [Reference Citation Analysis]
13 Ávila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne) 2021;8:642864. [PMID: 33898482 DOI: 10.3389/fmed.2021.642864] [Reference Citation Analysis]
14 Portoles J, Huerta A, Arjona E, Gavela E, Agüera M, Jiménez C, Cavero T, Marrero D, Rodríguez de Córdoba S, Diekmann F; Matrix Investigators . Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J 2021;14:1173-80. [PMID: 33841863 DOI: 10.1093/ckj/sfaa096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Aigner C, Gaggl M, Kain R, Prohászka Z, Garam N, Csuka D, Sunder-Plassmann R, Piggott LC, Haninger-Vacariu N, Schmidt A, Sunder-Plassmann G. Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy. J Clin Med 2020;9:E964. [PMID: 32244370 DOI: 10.3390/jcm9040964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Teixeira CM, Tedesco Silva Junior H, Moura LAR, Proença HMS, de Marco R, Gerbase de Lima M, Cristelli MP, Viana LA, Felipe CR, Medina Pestana JO. Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes. PLoS One 2020;15:e0227445. [PMID: 31923282 DOI: 10.1371/journal.pone.0227445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Braun F, Rinschen M, Buchner D, Bohl K, Plagmann I, Bachurski D, Richard Späth M, Antczak P, Göbel H, Klein C, Lackmann JW, Kretz O, Puelles VG, Wahba R, Hallek M, Schermer B, Benzing T, Huber TB, Beyer A, Stippel D, Kurschat CE, Müller RU. The proteomic landscape of small urinary extracellular vesicles during kidney transplantation. J Extracell Vesicles 2020;10:e12026. [PMID: 33304478 DOI: 10.1002/jev2.12026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Boudhabhay I, Rabant M, Roumenina LT, Coupry LM, Poillerat V, Marchal A, Frémeaux-Bacchi V, El Karoui K, Monchi M, Pourcine F. Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Front Immunol 2021;12:680567. [PMID: 34248962 DOI: 10.3389/fimmu.2021.680567] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Palma LMP, Eick RG, Dantas GC, Tino MKDS, de Holanda MI; Brazilian Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome Study Group (aHUS Brazil). Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J 2021;14:1126-35. [PMID: 33841858 DOI: 10.1093/ckj/sfaa062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Frimat M, Boudhabhay I, Roumenina LT. Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. Toxins (Basel) 2019;11:E660. [PMID: 31766155 DOI: 10.3390/toxins11110660] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
23 Deghmane AE, Taha MK. Invasive Bacterial Infections in Subjects with Genetic and Acquired Susceptibility and Impacts on Recommendations for Vaccination: A Narrative Review. Microorganisms 2021;9:467. [PMID: 33668334 DOI: 10.3390/microorganisms9030467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Fakhouri F, Scully M, Ardissino G, Al-Dakkak I, Miller B, Rondeau E. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. J Nephrol 2021. [PMID: 33826112 DOI: 10.1007/s40620-021-01025-x] [Reference Citation Analysis]
25 Kamel MH, Jaberi A, Gordon CE, Beck LH, Francis J. The Complement System in the Modern Era of Kidney Transplantation: Mechanisms of Injury and Targeted Therapies. Seminars in Nephrology 2022;42:14-28. [DOI: 10.1016/j.semnephrol.2022.01.006] [Reference Citation Analysis]
26 Teoh CW, Korus M, Lorenzo A, Langlois V. Preparing the Child with End-Stage Renal Disease for a Renal Transplant: the Pre-transplant Assessment. Curr Pediatr Rep 2020;8:134-46. [DOI: 10.1007/s40124-020-00225-6] [Reference Citation Analysis]
27 Bahougne T, Olagne J, Munch M, Braun-Parvez L, Chenard MP, Frémeaux-Bacchi V, Caillard S, Baltzinger P, Greget M, Kessler L, Moulin B. Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report. BMC Nephrol 2020;21:405. [PMID: 32950058 DOI: 10.1186/s12882-020-02062-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Timmermans SAMEG, van Paassen P. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J Clin Med 2021;10:3034. [PMID: 34300201 DOI: 10.3390/jcm10143034] [Reference Citation Analysis]
29 Nga HS, Palma LMP, Ernandes Neto M, Fernandes-Charpiot IMM, Garcia VD, Kist R, Miranda SMC, Macedo de Souza PA, Pereira GM Jr, de Andrade LGM. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort. PLoS One 2021;16:e0258319. [PMID: 34748552 DOI: 10.1371/journal.pone.0258319] [Reference Citation Analysis]
30 Ariceta G, Fakhouri F, Sartz L, Miller B, Nikolaou V, Cohen D, Siedlecki AM, Ardissino G. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clinical Kidney Journal 2021;14:2075-84. [DOI: 10.1093/ckj/sfab005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]